Eisspeedway

BFAI

BFAI
Clinical data
Other names5,6-Benzofuranyl-2-aminoindane; 5,6-Benzofuranyl-2-aminoindan
Drug classSelective serotonin releasing agent; Entactogen
ATC code
  • None
Identifiers
  • 6,7-dihydro-5H-cyclopenta[f][1]benzofuran-6-amine
PubChem CID
Chemical and physical data
FormulaC11H11NO
Molar mass173.215 g·mol−1
3D model (JSmol)
  • C1C(CC2=C1C=C3C=COC3=C2)N
  • InChI=1S/C11H11NO/c12-10-4-8-3-7-1-2-13-11(7)6-9(8)5-10/h1-3,6,10H,4-5,12H2
  • Key:SYCRQDBZPIEBIR-UHFFFAOYSA-N

BFAI (5,6-benzofuranyl-2-aminoindane) is a drug of the 2-aminoindane group that acts as a serotonin releasing agent (SSRA) and produces entactogen effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.[1] The drug was patented by Tactogen in 2022.[1]

See also

References

  1. ^ a b WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc. 
Quelle: https://en.wikipedia.org/wiki/BFAI